The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Bibliography

• DAVIES MJ, THOMAS AC: Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br. Heart J. (1985) 53:363–373.
   PubMedGoogle Scholar
• FALK E: Coronary thrombosis: pathogenesis and clini-cal manifestations. Am. J. Cardiol. (1991) 68:28B–35B.
   Google Scholar
• FALK E, SHAH PK, FUSTER V: Coronary plaque disrup-tion. Circulation (1995) 92:657–671.
   PubMed Web of Science ®Google Scholar
• FERGUSON JJ, WALY HM, WILSON JM: Fundamentals of coagulation and glycoprotein Ilb/IIIa receptor inhibi-tion. Eur. Heart J. (1998) 19 (Suppl. D):D3–D9.
   Google Scholar
• TIMI 3B INVESTIGATORS: Effects of tissue plasminogen activator and a comparison of early invasive and con-servative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation (1994) 89:1545–1556.
   PubMed Web of Science ®Google Scholar
• COLLER BS, PEERSCHKE El, SCUDDER LE, SULLIVAN CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins lib and/or Ma. J. Clin. Invest. (1983) 72:325–338.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, PLOW EF, TOPOL EJ: Platelet glycoprotein lib/Ilia receptors in cardiovascular medicine. New Eng. J. Med. (1995) 332:1553–1559.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, BYZOVA TV, PLOW EF: Platelet GP Ilb-IIIa blockers. Lancet (1999) 353:227–231.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Intergrins: a family of cell surface recep-tors. Cell (1987) 48:549–550.
   PubMed Web of Science ®Google Scholar
• COLLER BS: Blockade of platelet GP Ilb/IIIa receptors as an antithrombotic strategy. Circulation (1995) 92:2373–2380.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, TOPOL EJ: Platelet glycoprotein Ilb/IIIa receptor antagonists in coronary artery disease. Eur. Heart J. (1996) 17:9–18.
   PubMed Web of Science ®Google Scholar
• WAGNER CL, MASCELLI MA, NEBLOCK DS, WEISMAN HF, COLLER BS, JORDAN RE: Analysis of GP Ilb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88:9907–9914.
   Google Scholar
• MACKIE IJ: The biology of haemostasis and thrombo-sis. In: Oxford Textbook of Medicine (Third Edition, Volume 3). Haemostasis and Thrombosis. Weatherall DJ, LedinghamJGG, Warrell DA (Eds.), Oxford University Press Inc., New York (1996):3613–3627.
   Google Scholar
• BEVERS EM, COMFURIUS P, ZWAAL RF: Platelet proco-agulant activity: physiological significance and mechanisms of exposure. Blood Rev. (1991) 5:146–154.
   PubMed Web of Science ®Google Scholar
• CHARO IF, BEKEART LS, PHILIPS DR: Platelet glycopro-tein lib-IIIa like proteins mediate endothelial cell at-tachment to adhesive proteins and the extracellular matrix. J. Biol. Chem. (1987) 262:9935–9938.
   PubMed Web of Science ®Google Scholar
• FELDING-HABERMANN B, CHERESH DA: Vitronectin and its receptors. Curr. Opin. Cell Biol. (1993) 5:864–868.
   PubMed Web of Science ®Google Scholar
• CHOI ET, ENGEL L, CALLOW AD et al.: Inhibition of neointimal hyperplasia by blocking cc,63 intergrin with a small peptide antagonist GpenGRGDSPCA. J. Vasc. Surg. (1994) 19:125–134.
   PubMed Web of Science ®Google Scholar
• THE CAPTURE INVESTIGATORS: Randomized placebo-controlled trial of abciximab before and during coro-nary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349:1429–1435.
   PubMed Web of Science ®Google Scholar
• •Use of abciximab in ACS.
   Google Scholar
• SIMOONS ML, DE BOER MJ, VAN DEN BRAND MJBM et al.: Randomized trial of a GP Ilb/IIIa platelet receptor blocker in refractory unstable angina. Circulation (1994) 89:596–603.
   Google Scholar
• KLOOTWIJK P, MEIJ S, MELKERT R, LENDERINK T: Reduc-tion of recurrent ischaemia with abciximab during continuous ECG-ischaemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation (1998) 98:1358–1364.
   PubMed Web of Science ®Google Scholar
• GOULD RJ, CHANG CTC, LYNCH RJ et al.: MK-0383 is a potent non-peptide mimic of RGD that inhibits glyco-protein lib Ma. Throm. HaemosL (1993) 69:976.
   Google Scholar
• PEERLINCK K, DE LEPELEIRE I, GOLDBERG M et al.: MK-383 (L-700462), a selective non-peptide platelet glyco-protein Ilb/IIIa antagonist, is active in man. Circulation (1993) 88:1512–1517.
   PubMed Web of Science ®Google Scholar
• THE PLATELET RECEPTOR INHIBITION IN ISCHAEMIC SYNDROME MANAGEMENT (PRISM) STUDY INVESTIGA-TORS. A comparison of aspirin plus tirofiban with as-pirin plus heparin for unstable angina. New Eng. J. Med. (1998) 338:1498–1505.
   Google Scholar
• •Use of tirofiban in ACS.
   Google Scholar
• THE PLATELET RECEPTOR INHIBITION IN ISCHAEMIC SYNDROME MANAGEMENT IN-PATIENTS LIMITED BY UNSTABLE SIGNS AND SYMPTOMS (PRISM-PLUS) STUDY INVESTIGATORS: Inhibition of the platelet glycopro-tein Ilb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Eng. J. Med. (1998) 338:1488–1497.
   PubMed Web of Science ®Google Scholar
• ••Use of tirofiban in high risk ACS.
   Google Scholar
• CHESEBRO JH, BADIMON JJ: Platelet glycoproteinIlb/IIIa receptor blockade in unstable coronary dis-ease. New Eng. J. Med. (1998) 338(21):1539–1541.
   PubMed Web of Science ®Google Scholar
• ALIG L, EDENHOFER A, HADVARY P, HeRZELER M, KNOPP D, WILLER M et al.: Low molecular weight, non-peptide fibrinogen receptor antagonists. J. Med. Chem. (1992) 35:4393–4407.
   PubMed Web of Science ®Google Scholar
• KOUNS WC, KIRCHOFER D, HADVARY P et al: Reversible conformational changes induced in glycoprotein Ilb/Ifia by a potent and selective peptidomimetic in-hibitor. Blood (1992) 80:2539–3547.
   PubMed Web of Science ®Google Scholar
• THÉROUX P, KOUZ S, ROY L, KNUDTSON ML, DIODATI JG, MARQUIS J-F et al. ON BEHALF OF THE INVESTIGA-TORS: Platelet membrane receptor glycoprotein Ilb/Ifia antagonism in unstable angina: The Canadian Lamifiban Study. Circulation (1996) 94:899–905.
   PubMed Web of Science ®Google Scholar
• •Use of lamifiban in ACS.
   Google Scholar
• THE PARAGON INVESTIGATORS: An international, ran-domized, controlled trial of lamifiban, a platelet glyco-protein Ilb/Ifia inhibitor, heparin or both in unstable angina. Circulation (1998) 97:2386–2395.
   PubMed Web of Science ®Google Scholar
• •Use of lamifiban ± heparin.
   Google Scholar
• PHILIPS DR, TENG W, ARFSTEN A et al: Effect of Ca2+ onGP Ilb-Ifia interactions with Intergrilin: enhanced GP fiblfia binding and inhibition of platelet aggregation by reductions in the concentrations of ionised calcium in plasma anticoagulated with citrate. Circulation (1997) 96:1488–1494.
   PubMed Web of Science ®Google Scholar
• HARRINGTON RA, KLEIMAN NS, KOTTKE-MARCHANT K et al.: Immediate and reversible platelet inhibition af-ter intravenous administration of a peptide glycopro-tein Ilb/Ifia inhibitor during percutaneous coronary intervention. Am. J. Cardiol (1995) 76:1222–7.
   PubMed Web of Science ®Google Scholar
• TCHENG JE, HARRINGTON RA, KOTTKE-MARCHANT K et al.: Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein Ilb/Ifia blocker Integrelin in elective coronary inter-vention. Circulation (1995) 91:2151–7.
   PubMed Web of Science ®Google Scholar
• THE IMPACT-II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complica-tions of percutaneous coronary intervention: IMPACT-II. Lancet (1997) 349:1422–8.
   PubMed Web of Science ®Google Scholar
• SCHULMAN SP, GOLDSCHMIDT-CLERMONT PJ, TOPOL EJet al.: Effects of Integrelin, a platelet glycoprotein Ilb/Ifia receptor antagonist, in unstable angina: a ran-domized multicenter trial. Circulation (1996) 94:2083–9.
   Google Scholar
• THE PURSUIT TRIAL INVESTIGATORS: Inhibition ofplatelet glycoprotein Ilb/Ifia with eptifibatide in pa-tients with acute coronary syndromes. New Eng. J. Med. (1998) 339:436–443.
   PubMed Web of Science ®Google Scholar
• •Use of eptifibatide in ACS.
   Google Scholar
• WELLER T, ALIG L, BERESINI M et al.: Orally active fi-brinogen receptor antagonists, 2: amidoximes as prodrugs of amidines. J. Med. Chem. (1996) 39:3139–3147.
   PubMed Web of Science ®Google Scholar
• CANNON CP, MCCABE CH, BORZAK S et al: FOR THE TIMI12 INVESTIGATORS: Randomized trial of an oral plate-let glycoprotein Ilb/Ifia antagonist, sibrafiban, in pa-tients after an acute coronary syndrome. Results of the TIMI 12 Trial. Circulation (1998) 97:340–349.
   PubMed Web of Science ®Google Scholar
• •Use of sibrafiban in ACS.
   Google Scholar
• CHESEBRO JH, KNATTERUD G, ROBERTS R et al: Throm-bolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation (1987) 76:142–157.
   PubMed Web of Science ®Google Scholar
• ANTMEN EM, FOR THE TIMI 9B INVESTIGATORS: Hi-rudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation (1996) 94:911–921.
   PubMed Web of Science ®Google Scholar
• THE EPIC INVESTIGATORS: Use of a monoclonal anti-body directed against the platelet glycoprotein Ilb/Ifia receptor in high-risk coronary angioplasty. New Eng. J. Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, CALIFF RM, WEISMAN HF et al.: Randomisedtrial of coronary intervention with antibody against platelet Ilb/Ifia integrin for reduction of clinical res-tenosis: results at six months. Lancet (1994) 343:881–886.
   PubMed Web of Science ®Google Scholar
• CALIFF RM, LINCOFF AM, TCHENG JE, TOPOL EJ: An over-view of the results of the EPIC trial. Eur. Heart J. (1995) 16(Suppl 0:43–49.
   PubMedGoogle Scholar
• LINCOFF AM, CALIFF RM, ANDERSON KM et al: Evidence for prevention of death and MI with platelet mem-brane glycoprotein Ilb/Ifia receptor blockade by ab-ciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascu-larization. J. Am. Coll Cardiol (1997) 30:149–156.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, FERGUSON JJ, WEISMAN HF et al: Long-term protection from myocardial ischaemic events in a ran-domized trial of brief integrin b3 blockade with percu-taneous coronary intervention. JAMA (1997) 278:479–484.
   PubMed Web of Science ®Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoprotein Ilb/Ifia receptor blockade and low-dose heparin dur-ing percutaneous coronary revascularization. New Eng. J. Med. (1997) 336:1689–1696.
   PubMed Web of Science ®Google Scholar
• THE EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein Ilb/Ifia blockade. Lancet (1998) 352:87–92.
   PubMed Web of Science ®Google Scholar
• THE RESTORE INVESTIGATORS: Effects of platelet glyco-protein Ilb/Ifia blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary an-gioplasty. Circulation (1997) 96:1445–1453.
   PubMed Web of Science ®Google Scholar
• THE IMPACT-II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complica-tions of percutaneous coronary intervention: IMPACT-II. Lancet (1997) 349:1422–1418.
   PubMed Web of Science ®Google Scholar
• KEREIAKES DJ, KLEIMAN NS, FERGUSON JJ et al: FOR THE ORBIT TRIAL INVESTIGATORS: Pharmacodynamic effi-cacy, clinical safety, and outcomes after prolonged platelet glycoprotein Ilb/Ifia receptor blockade with oral xemilofiban. Circulation (1998) 98:1268–1278.
   PubMed Web of Science ®Google Scholar
• AGUIRRE FV, TOPOL EJ, FERGUSON JJ et al.: Bleeding complications with the chimeric antibody to platelet glycoprotein Ilb/Ifia integrin in patients undergoing percutaneous coronary intervention. Circulation (1995) 91:2882–2890.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ: Toward a new frontier in myocardial reper-fusion therapy: emerging platelet preeminence. Circu-lation (1998) 97:211–218.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, LINCOFF AM, SAPP S: Coronary stenting anduse of abciximab. Lancet (1998) 352:1311–1312.
   PubMed Web of Science ®Google Scholar
• FERGUSON JJ, KEREIAKES DJ, ADGEY AAJ et al.: Safe useof platelet GP Ilb/IIIa inhibitors. Eur. Heart J. (1998) 19(Suppl D):D40–D51.
   Google Scholar
• THE PARADIGM INVESTIGATORS: Combining throm-bolysis with the platelet glycoprotein Ilb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J. Am. Coll. Cardiol (1998) 32:2003–2010.
   PubMed Web of Science ®Google Scholar
• GOKLANEY AK, MURPHY JD, HILLEGASS JR. WB: Abcixi-mab therapy in percutaneous intervention: Economic issues in the United States. Eur. Heart J. (1998) 19(Suppl D):D52–D58.
   Google Scholar
• VAN HOUT BA, BOWMAN L, ZELINGER DJ, SIMOONS ML:Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergo-ing percutaneous transluminal coronary angioplasty in the EPIC study. Eur. Heart 1 (1998) 19(Suppl D):D59–D66.
   Google Scholar
• MARK DB, TALLEY JD, TOPOL EJ et al.: Economic assess-ment of platelet glycoprotein Ilb/IIIa inhibition for prevention of ischaemic complications of high risk coronary angiography (The EPIC Investigators). Circu-lation (1996) 94 (4) :629–635.
   PubMedGoogle Scholar
• IMPACT-AMI INVESTIGATORS: Combined accelerated tissue-plasminogen activator and plateletglycoprotein Ilb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation (1997) 95:846–854.
   PubMed Web of Science ®Google Scholar
• KLEIMAN MS, OHMAN EM, CALIFF RM et al: Profound in-hibition of platelet aggregation with monoclonal anti-body 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarc-tion (TAMO 8 pilot Group. Am. Coll. Cardiol. (1993) 22:381–389.
   PubMed Web of Science ®Google Scholar
• BRENER SJ, BARR LA, BURCHENAL JE, KATZ S, GEORGEBS, JONES AA et al.: A randomized placebo-controlled trial of abciximab with primary angioplasty for acute MI: the RAPPORT trial. Circulation (1998) 98 (Part 8)734–741
   Google Scholar
• CANNON CP, WEINTRAUB WS, DEMOPOULUS LA et al:Invasive versus conservative strategies in unstable an-gina and non-Q-wave myocardial infarction following treatment with tirofiban: rational and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am. J. Cardiol. (1998) 82(6):731–736.Ganesh Manoharan, Suzanne J Maynard & AA Jennifer Adgeyt tAuthor for correspondenceRegional Medical Cardiology Centre, Royal Victoria Hospital, Grosvenor Road, Belfast. BT12 6BA, UKTel.: +44 1232 894975; Fax: +44 1232 312907
   Google Scholar